vs
Side-by-side financial comparison of AMBARELLA INC (AMBA) and DYNAVAX TECHNOLOGIES CORP (DVAX). Click either name above to swap in a different company.
AMBARELLA INC is the larger business by last-quarter revenue ($108.5M vs $94.9M, roughly 1.1× DYNAVAX TECHNOLOGIES CORP). DYNAVAX TECHNOLOGIES CORP runs the higher net margin — 28.4% vs -13.9%, a 42.3% gap on every dollar of revenue. On growth, AMBARELLA INC posted the faster year-over-year revenue change (31.2% vs 17.7%). DYNAVAX TECHNOLOGIES CORP produced more free cash flow last quarter ($32.6M vs $31.4M). Over the past eight quarters, AMBARELLA INC's revenue compounded faster (45.0% CAGR vs 30.6%).
Ambarella, Inc. is an American fabless semiconductor design company, focusing on low-power, high-definition (HD) and Ultra HD video compression, image processing, and computer vision processors. Ambarella's products are used in a wide variety of human and computer vision applications, including video security, advanced driver assistance systems (ADAS), electronic mirror, drive recorder, driver and in-cabin monitoring, autonomous driving, and robotics applications. Ambarella's system on chips ...
Dynavax Technologies Corp is a commercial-stage biopharmaceutical company specializing in the research, development, and production of innovative vaccines and immunotherapies for infectious diseases. Its lead approved product is Heplisav-B, an adult hepatitis B vaccine, with core markets in North America and Europe, alongside a pipeline of candidates addressing unmet public health needs.
AMBA vs DVAX — Head-to-Head
Income Statement — Q3 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $108.5M | $94.9M |
| Net Profit | $-15.1M | $26.9M |
| Gross Margin | 59.6% | — |
| Operating Margin | -15.0% | 22.4% |
| Net Margin | -13.9% | 28.4% |
| Revenue YoY | 31.2% | 17.7% |
| Net Profit YoY | 37.2% | 53.0% |
| EPS (diluted) | $-0.35 | $0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $108.5M | — | ||
| Q3 25 | $95.5M | $94.9M | ||
| Q2 25 | $85.9M | $95.4M | ||
| Q1 25 | $84.0M | $68.2M | ||
| Q4 24 | $82.7M | $72.0M | ||
| Q3 24 | $63.7M | $80.6M | ||
| Q2 24 | $54.5M | $73.8M | ||
| Q1 24 | $51.6M | $50.8M |
| Q4 25 | $-15.1M | — | ||
| Q3 25 | $-20.0M | $26.9M | ||
| Q2 25 | $-24.3M | $18.7M | ||
| Q1 25 | $-20.2M | $-96.1M | ||
| Q4 24 | $-24.1M | $7.0M | ||
| Q3 24 | $-34.9M | $17.6M | ||
| Q2 24 | $-37.9M | $11.4M | ||
| Q1 24 | $-60.6M | $-8.7M |
| Q4 25 | 59.6% | — | ||
| Q3 25 | 58.9% | — | ||
| Q2 25 | 60.0% | — | ||
| Q1 25 | 60.0% | — | ||
| Q4 24 | 60.6% | — | ||
| Q3 24 | 60.8% | — | ||
| Q2 24 | 60.9% | — | ||
| Q1 24 | 59.8% | — |
| Q4 25 | -15.0% | — | ||
| Q3 25 | -23.0% | 22.4% | ||
| Q2 25 | -30.1% | 15.1% | ||
| Q1 25 | -30.2% | -34.7% | ||
| Q4 24 | -30.9% | -2.3% | ||
| Q3 24 | -56.9% | 12.5% | ||
| Q2 24 | -72.4% | 7.0% | ||
| Q1 24 | -80.8% | -35.0% |
| Q4 25 | -13.9% | — | ||
| Q3 25 | -20.9% | 28.4% | ||
| Q2 25 | -28.3% | 19.6% | ||
| Q1 25 | -24.1% | -141.0% | ||
| Q4 24 | -29.1% | 9.8% | ||
| Q3 24 | -54.8% | 21.8% | ||
| Q2 24 | -69.6% | 15.4% | ||
| Q1 24 | -117.4% | -17.2% |
| Q4 25 | $-0.35 | — | ||
| Q3 25 | $-0.47 | $0.21 | ||
| Q2 25 | $-0.58 | $0.14 | ||
| Q1 25 | $-0.48 | $-0.77 | ||
| Q4 24 | $-0.58 | $0.07 | ||
| Q3 24 | $-0.85 | $0.12 | ||
| Q2 24 | $-0.93 | $0.08 | ||
| Q1 24 | $-1.51 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $174.1M | $160.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $590.1M | $534.1M |
| Total Assets | $751.9M | $946.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $174.1M | — | ||
| Q3 25 | $142.7M | $160.2M | ||
| Q2 25 | $141.3M | $99.1M | ||
| Q1 25 | $144.6M | $51.7M | ||
| Q4 24 | $127.1M | $95.9M | ||
| Q3 24 | $153.9M | $119.3M | ||
| Q2 24 | $131.8M | $112.5M | ||
| Q1 24 | $144.9M | $132.0M |
| Q4 25 | $590.1M | — | ||
| Q3 25 | $576.5M | $534.1M | ||
| Q2 25 | $572.7M | $494.2M | ||
| Q1 25 | $561.4M | $530.9M | ||
| Q4 24 | $554.3M | $596.8M | ||
| Q3 24 | $547.6M | $681.4M | ||
| Q2 24 | $555.4M | $642.8M | ||
| Q1 24 | $559.9M | $618.5M |
| Q4 25 | $751.9M | — | ||
| Q3 25 | $706.4M | $946.5M | ||
| Q2 25 | $701.9M | $918.4M | ||
| Q1 25 | $689.0M | $945.9M | ||
| Q4 24 | $670.8M | $986.3M | ||
| Q3 24 | $650.3M | $1.1B | ||
| Q2 24 | $638.7M | $1.0B | ||
| Q1 24 | $657.7M | $986.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $34.3M | $33.8M |
| Free Cash FlowOCF − Capex | $31.4M | $32.6M |
| FCF MarginFCF / Revenue | 29.0% | 34.4% |
| Capex IntensityCapex / Revenue | 2.7% | 1.3% |
| Cash ConversionOCF / Net Profit | — | 1.26× |
| TTM Free Cash FlowTrailing 4 quarters | $64.3M | $80.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $34.3M | — | ||
| Q3 25 | $5.5M | $33.8M | ||
| Q2 25 | $14.8M | $23.4M | ||
| Q1 25 | $25.4M | $-19.6M | ||
| Q4 24 | $6.6M | $53.0M | ||
| Q3 24 | $16.7M | $19.5M | ||
| Q2 24 | $-15.0M | $10.7M | ||
| Q1 24 | $-4.0M | $-16.7M |
| Q4 25 | $31.4M | — | ||
| Q3 25 | $1.4M | $32.6M | ||
| Q2 25 | $10.2M | $22.0M | ||
| Q1 25 | $21.2M | $-23.6M | ||
| Q4 24 | $4.1M | $49.5M | ||
| Q3 24 | $14.2M | $18.1M | ||
| Q2 24 | $-16.1M | $9.9M | ||
| Q1 24 | $-6.0M | $-17.4M |
| Q4 25 | 29.0% | — | ||
| Q3 25 | 1.4% | 34.4% | ||
| Q2 25 | 11.9% | 23.0% | ||
| Q1 25 | 25.3% | -34.6% | ||
| Q4 24 | 5.0% | 68.8% | ||
| Q3 24 | 22.2% | 22.5% | ||
| Q2 24 | -29.5% | 13.5% | ||
| Q1 24 | -11.6% | -34.3% |
| Q4 25 | 2.7% | — | ||
| Q3 25 | 4.3% | 1.3% | ||
| Q2 25 | 5.3% | 1.5% | ||
| Q1 25 | 5.0% | 5.8% | ||
| Q4 24 | 3.0% | 4.8% | ||
| Q3 24 | 4.0% | 1.7% | ||
| Q2 24 | 2.1% | 1.1% | ||
| Q1 24 | 3.7% | 1.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.26× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 7.52× | ||
| Q3 24 | — | 1.11× | ||
| Q2 24 | — | 0.94× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMBA
| TW | $76.0M | 70% |
| Asia Pacific Other Than Taiwan | $20.2M | 19% |
| North America Other Than United States | $7.4M | 7% |
| Other | $5.0M | 5% |
DVAX
| HEPLISAVB | $90.0M | 95% |
| US Department Of Defense | $4.7M | 5% |
